Home
World Journal of Biological and Pharmaceutical Research
Peer-Reviewed • ISSN: 2799-0338 • Impact Factor 7.8

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

🌟 🧬 World Journal of Biological and Pharmaceutical Research (WJBPR) 🧬 🌟

Low-Cost Journal Publication | CrossRef DOI | Transparent Peer Review Process

International, Open Access, Peer-Reviewed, Multidisciplinary Journal in Biological and Pharmaceutical Sciences, Indexed in Major Databases, DOI Assignment (Crossref)

ISSN: 2799-0338 | Impact Factor: 7.8 | ESTD Year: 2021 | Charges 35 USD

Published paper PDF, E-certificate of publication, Official letter of acceptance, Peer review report, Cover page, Editorial information, and Indexing details.

📄 Submit Paper 👉 Author Guidelines

Diclofenac sodium and Allopurinol induced Stevens Johnson Syndrome in pulmonary tuberculosis patients receiving intensive phase first-line antituberculosis drugs

Breadcrumb

  • Home
  • Diclofenac sodium and Allopurinol induced Stevens Johnson Syndrome in pulmonary tuberculosis patients receiving intensive phase first-line antituberculosis drugs

Desdiani Desdiani *

Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Sultan Ageng Tirtayasa University, Serang, Banten, Indonesia.
 

Research Article
World Journal of Biological and Pharmaceutical Research, 2023, 04(02), 010–013.
Article DOI: 10.53346/wjbpr.2023.4.2.0051
DOI url: https://doi.org/10.53346/wjbpr.2023.4.2.0051

Received on 23 April  2023; revised on 02 June 2023; accepted on 05 June 2023
 

One of the life-threatening multi-organ emergency conditions is Stevens-Johnson Syndrome (SJS). Although this is a rare disease and manifests as drug reactions, this condition can cause death.We present a case of a 63-year-old male with Diclofenac sodium and Allopurinol induced Stevens_Johnson Syndrome in pulmonary tuberculosis patients receiving intensive phase first-line antituberculosis drugs.The patient was undergoing outpatient TB treatment at the end of the first month. The patient comes to the emergency department of the hospital because of shortness of breath, fever, blistered skin, nasal and oral mucosa, cracks and wounds, visible pus, red eyes accompanied by erythematous rash all over the body after previously taking diclofenac sodium and allopurinol given by the doctor because felt joint pain all over body and uric acid increased. On physical examination of the lungs, crackles and wheezing were heard in both lung fields. The chest radiograph shows infiltrates in both lung fields. Laboratory results showed leukocytosis and the results of other blood laboratory tests were still within normal limits. Patient diagnosed Stevens-Johnson Syndrome based on clinical, laboratory, and radiology examination results. The patient was given treatments using nasal canule oxygen of 5 litres/minute, intravenous fluid dehydration D5% : NaCl 0.9%, ceftriaxone injection, gentamicin injection, dexamethasone injection, cetirizine ranitidine injection, compresses with 0.9% NaCl liquid, 2.5% hydrocortisone ointment. The patient was treated in the Intensive Care Unit for 8 days. The patient had no history of previous drug allergies. In this case, the likelihood of Diclofenac sodium and Allopurinol induced Stevens_Johnson Syndrome in pulmonary tuberculosis patients receiving intensive phase first-line antituberculosis drugs, needs to be a concerned, as well as the importance of evaluation and strict follow-up to prevent Stevens Johnson Syndrome disease.
 

Stevens Johnson Syndrome; Diclofenac sodium; Allopurinol; Antituberculosis drug

https://wjbpr.zealjournals.com/sites/default/files/fulltext_pdf/WJBPR-2023-0051…

Preview Article PDF

Desdiani Desdiani. Diclofenac sodium and Allopurinol induced Stevens Johnson Syndrome in pulmonary tuberculosis patients receiving intensive phase first-line antituberculosis drugs. World Journal of Biological and Pharmaceutical Research, 2023, 04(02), 010–013. Article DOI: https://doi.org/10.53346/wjbpr.2023.4.2.0051

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 World Journal of Biological and Pharmaceutical Research - All rights reserved

Developed & Designed by VS Infosolution